^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    PSMD14 (Proteasome 26S Subunit, Non-ATPase 14)

    i
    Other names: Proteasome 26S Subunit, Non-ATPase 14, POH1, Proteasome (Prosome, Macropain) 26S Subunit, Non-ATPase, 14, 26S Proteasome Non-ATPase Regulatory Subunit 14, 26S Proteasome-Associated PAD1 Homolog 1, Testis Tissue Sperm-Binding Protein Li 69n, 26S Proteasome Regulatory Subunit Rpn11, 26S Proteasome Regulatory Subunit RPN11, PSMD14, RPN11, Rpn11, PAD1, Pad1
    Associations

    News

    Trials
    17d
    Targeting the PSMD14-BCKDK pathway overcomes immune suppression and enhances CAR-NK infiltration in glioblastoma. (PubMed, Cell Death Differ)
    Clinical analysis further establishes that elevated PSMD14 and BCKDK expression in GBM correlates with decreased CD8+ T and NK cell infiltration and poorer patient survival. These findings highlight the PSMD14-BCKDK axis as a central regulator of tumor metabolic adaptation and immune suppression, and support PSMD14 inhibition-alone or in combination with CAR-NK therapy-as a promising strategy for precision immunometabolic intervention in GBM.
    Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • SLC7A5 (Solute Carrier Family 7 Member 5) • IGF2BP3 (Insulin Like Growth Factor 2 MRNA Binding Protein 3) • PSMD14 (Proteasome 26S Subunit, Non-ATPase 14) • TRIM21 (Tripartite Motif Containing 21)
    1m
    L-lactate-driven PSMD14 lactylation and stabilization promote lactate production and ferroptosis resistance via ENO1 in intrahepatic cholangiocarcinoma. (PubMed, Cancer Lett)
    Furthermore, PSMD14 and ENO1 were highly expressed in tumor tissues and closely associated with a poor ICC prognosis. Overall, our study reveals the importance of the L-lactate/PSMD14/ENO1 axis in regulating ferroptosis resistance in ICC, suggesting a novel therapeutic target and strategy for treating this disease.
    Journal
    |
    ENO1 (Enolase 1) • PSMD14 (Proteasome 26S Subunit, Non-ATPase 14)
    1m
    FOXM1 Signaling Network Transcriptionally Upregulates Expression of Proteins Involved in Mitotic Progression to Induce High Proliferation and Chromosomal Instability in Androgen Receptor-Low Triple-Negative Breast Cancer. (PubMed, Int J Mol Sci)
    In light of prior work, our findings point to a FOXM1-associated 15-gene signature enriched in AR-low TNBC and associated with the high-proliferation and high-CIN phenotypes of this clinically challenging tumor type. This 15-gene set represents an actionable vulnerability with therapeutic potential for AR-low TNBC and provides a framework for rethinking how to manage highly proliferative, genomically unstable BCs.
    Journal
    |
    TP53 (Tumor protein P53) • AR (Androgen receptor) • FOXM1 (Forkhead Box M1) • PCNA (Proliferating cell nuclear antigen) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • KIF11 (Kinesin Family Member 11) • WDR5 (WD Repeat Domain 5) • CENPA (Centromere protein A) • KIF20A (Kinesin Family Member 20A) • KIF2C (Kinesin Family Member 2C) • KIF4A (Kinesin Family Member 4A) • MCM2 (Minichromosome maintenance complex component 2) • PSMD14 (Proteasome 26S Subunit, Non-ATPase 14) • SPDEF (SAM Pointed Domain Containing ETS Transcription Factor) • UBE2C (Ubiquitin Conjugating Enzyme E2 C) • TUBA1B (Tubulin Alpha 1b)
    |
    TP53 mutation
    2ms
    Covalent targeting of PSMD14 by Eupalinolide B induces oncoprotein degradation and apoptosis in acute promyelocytic leukemia cells. (PubMed, RSC Chem Biol)
    Both genetic knockdown and pharmacological inhibition of PSMD14 recapitulate EB's effects, confirming its essential role in leukemia cell survival and proliferation. Collectively, these findings uncover a previously unrecognized PSMD14-AKT1/CDK4 regulatory axis in leukemia and position EB as a promising chemical probe and lead compound for the development of targeted covalent inhibitors against oncogenic DUBs.
    Journal
    |
    AKT1 (V-akt murine thymoma viral oncogene homolog 1) • CDK4 (Cyclin-dependent kinase 4) • CDK7 (Cyclin Dependent Kinase 7) • PSMD1 (Proteasome 26S Subunit Non-ATPase 1) • PSMD14 (Proteasome 26S Subunit, Non-ATPase 14)
    2ms
    Coupling proteostasis and de novo purine biosynthesis of PSMD14 fuels glioblastoma progression and chemoresistance. (PubMed, Theranostics)
    PSMD14-IMPDH2 axis serves as a crucial hub integrating post-translational modifications and metabolic homeostasis in GBM. Targeting PSMD14 enhances therapeutic sensitivity, presenting a promising strategy to overcome TMZ resistance and improve GBM treatment efficacy.
    Journal
    |
    PSMD14 (Proteasome 26S Subunit, Non-ATPase 14)
    3ms
    Exosomal CircUBR5 Drives Metastasis and Chemoresistance in Gastric Signet-Ring Cell Carcinoma by Reprogramming Cholesterol Metabolism Through the hsa-miR-1208/CYP19A1 Axis and ACAT1 Upregulation. (PubMed, Cancer Lett)
    Notably, combining circUBR5-targeting antisense oligonucleotides with cisplatin synergistically inhibited tumor growth and reversed chemoresistance in vivo. Thus, circUBR5 promotes GSRCC progression through dual pathways coordinating estrogen signaling and cholesterol metabolism, and its exosomal dissemination facilitates chemoresistance induction within the tumor microenvironment, highlighting its potential as a prognostic biomarker and therapeutic target.
    Journal
    |
    ACAT1 (Acetyl-CoA Acetyltransferase 1) • PSMD14 (Proteasome 26S Subunit, Non-ATPase 14) • UBR5 (Ubiquitin Protein Ligase E3 Component N-Recognin 5)
    |
    cisplatin
    3ms
    PSMD14 drives lung adenocarcinoma progression through HMMR stabilization and dual activation of TGF-β/Smad and PI3K/AKT/mTOR signaling. (PubMed, Front Immunol)
    The PSMD14 inhibitor Capzimin exhibited potent anti-tumor effects in vitro and in vivo, and combination therapy with the TGF-β inhibitor galunisertib demonstrated enhanced efficacy...Consequently, the PSMD14-HMMR axis emerges as a promising therapeutic target. Inhibition of PSMD14 exhibited significant anti-tumor efficacy, underscoring its potential for clinical translation in LUAD treatment.
    Journal
    |
    TGFB1 (Transforming Growth Factor Beta 1) • HMMR (Hyaluronan Mediated Motility Receptor) • PSMD14 (Proteasome 26S Subunit, Non-ATPase 14)
    |
    galunisertib (LY2157299)
    5ms
    PSMD14-mediated PFKFB2 deubiquitination activates H3K27 lactylation to drive cancer stemness in gastric adenocarcinoma. (PubMed, Cell Death Differ)
    Notably, high-throughput screening of FDA-approved drugs reveals that Daclatasvir (DCV) exhibits high binding affinity for PSMD14 protein, disrupts the PSMD14-PFKFB2 interaction, reduces PFKFB2 activity and tumor burden. Collectively, our findings are the first to elucidate a positive feedback loop existing between PSMD14 and glycolysis in GAC progression, suggesting that PSMD14 blockade may represent a potential therapeutic approach for GAC.
    Journal
    |
    SOX9 (SRY-Box Transcription Factor 9) • PSMD14 (Proteasome 26S Subunit, Non-ATPase 14)
    6ms
    PSMD14-Mediated LDHA Deubiquitination Upregulates ACLY Expression via H3K18 Lactylation to Promote Lipid Synthesis and Pancreatic Cancer Progression. (PubMed, Adv Sci (Weinh))
    This study reveals a previously unrecognized role of PSMD14-derived lactate in mediating histone lactylation-coupled lipid deposition and tumor progression. Therapeutic co-targeting of PSMD14 and glycolytic lactylation significantly suppresses tumor growth in patient-derived xenograft models, suggesting a promising combinatorial strategy for pancreatic cancer treatment.
    Journal
    |
    LDHA (Lactate dehydrogenase A) • ACLY (ATP Citrate Lyase) • PSMD14 (Proteasome 26S Subunit, Non-ATPase 14)
    6ms
    Novel drug research and therapeutic strategies targeting tumor metastasis and cancer stem cells. (PubMed, Front Pharmacol)
    PTC 209 utilizes the high affinity of modified hyaluronic acid nanoparticles for colorectal cancer to reverse CSC stemness in colorectal cancer...These strategies emphasize specificity, nanodelivery, and combination therapies to reduce toxicity and resistance, highlighting precision oncology potential. Clinical validation remains critical for translation.
    Review • Journal
    |
    PSMD14 (Proteasome 26S Subunit, Non-ATPase 14)
    |
    PTC-209
    7ms
    Integrated multi-omics analysis reveals PTM networks as key regulators of colorectal cancer progression and immune evasion. (PubMed, Discov Oncol)
    This study establishes PTM networks as central regulators of CRC progression and immune resistance. The PTM-AS framework enables precision subtyping, while GALNT6 emerges as a novel therapeutic target for overcoming immunotherapy resistance.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • PSMD14 (Proteasome 26S Subunit, Non-ATPase 14) • UBE2C (Ubiquitin Conjugating Enzyme E2 C)
    7ms
    A Metabolism-Driven Prognostic Model and PSMD14-SP1-GYS1 Axis Reveal Therapeutic Vulnerabilities in Melanoma. (PubMed, J Invest Dermatol)
    In vivo validation confirmed that PSMD14 knockdown suppressed tumor growth via SP1-GYS1 axis disruption. This work establishes MRPM as a robust predictive tool and elucidates the PSMD14-SP1-GYS1 regulatory network as a potential therapeutic target in melanoma metabolism.
    Journal • IO biomarker
    |
    PSMD14 (Proteasome 26S Subunit, Non-ATPase 14)